Johnson & Johnson Q3 net earnings fall 96% to $210 million; sales rise 6% to $25.4 billion

Johnson & Johnson posted Q3 2026 net earnings of USD 210 million, swinging from profit a year earlier. Reported sales rose 6% to USD 25.4 billion versus Q3 2025. * Innovative Medicine net sales climbed 8% to USD 16.76 billion, while MedTech net sales increased to USD 8.64 billion. CEO Joaquín Duato cited “accelerating momentum” and highlighted OTTAVA progress and positive Phase 3 multiple myeloma results. 2026 reported sales guidance increased to USD 101.0 billion—USD 101.4 billion, with adjusted EPS guidance lifted to USD 11.05—USD 11.15. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Johnson & Johnson published the original content used to generate this news brief via (Ref. ID: 20261013290017) on October 13, 2026, and is solely responsible for the information contained therein. (C)